The short answer
No. Treatment consent addresses clinical decisions; a good faith estimate addresses expected charges in applicable uninsured/self-pay situations; an ABN addresses specified Original Medicare noncoverage situations. Marketing authorization is another separate decision. Match each document to its purpose and applicable requirements.
Keep the financial documents distinct
CMS describes the ABN and the uninsured/self-pay estimate as different processes. A signature on one document does not automatically satisfy the other. Use the current official instructions and forms where applicable; do not combine away required disclosures for a shorter intake packet.
Separate permission to treat from permission to publish
HHS marketing rules address uses and disclosures of PHI for marketing. A clinical consent should not be treated as blanket permission to advertise with patient images or stories. Clinical informed-consent requirements themselves depend on the service and applicable law.
Your practical checklist
- Map each document to its clinical, financial or privacy purpose.
- Identify the patient and service situations that trigger it.
- Have the applicable forms reviewed and version controlled.
- Track delivery or signature requirements separately for each document.
A worked example
A packet has a single “I agree” checkbox below treatment consent, marketing photos and all payment terms. That design obscures distinct decisions. Rework the intake flow so each applicable document and choice is understandable and its evidence can be retrieved.
Illustrative workflow example; not a patient case or individualized recommendation.
Mistakes to avoid
- Calling a payment authorization informed clinical consent.
- Using an ABN for every payer.
- Treating consent to treatment as authorization for social media.